171 related articles for article (PubMed ID: 37421190)
1. Severe infections in Portuguese patients with rheumatoid arthritis under biologic treatment - a multicenter, nationwide study (SIPPRA-B Study).
Oliveira Pinheiro F; Seabra Rato M; Madureira P; Araújo F; Salvador MJ; Fraga V; Brites L; Cunha Santos F; Silva A; Lopes AR; Cruz M; Vilas Boas JP; Pontes Ferreira M; Samões B; Beirão T; Santos I; Carvalho D; Costa L; Bernardes M
ARP Rheumatol; 2023; 2(2):111-119. PubMed ID: 37421190
[TBL] [Abstract][Full Text] [Related]
2. Predictors and causes of first-line biologic agent discontinuation in rheumatoid arthritis: data from Reuma.pt.
Gomes JL; Sepriano A; Eusébio M; Serra S; Fonseca JE; Saavedra MJ; Cunha-Miranda L; Silva C; Bernardes M; Rosa-Gonçalves D; Costa J; Castelão W; Branco JC; Santos MJ
Acta Reumatol Port; 2019; 44(1):57-64. PubMed ID: 31249276
[TBL] [Abstract][Full Text] [Related]
3. Ten-year retrospective review of the incidence of serious infections in patients on biologic disease modifying agents for rheumatoid arthritis in three tertiary hospitals in Western Australia.
Sharma C; Keen H
Intern Med J; 2019 Apr; 49(4):519-525. PubMed ID: 30230146
[TBL] [Abstract][Full Text] [Related]
4. Biologic refractory disease in rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis.
Kearsley-Fleet L; Davies R; De Cock D; Watson KD; Lunt M; Buch MH; Isaacs JD; Hyrich KL;
Ann Rheum Dis; 2018 Oct; 77(10):1405-1412. PubMed ID: 29980575
[TBL] [Abstract][Full Text] [Related]
5. Predictive factors for switching in patients with psoriatic arthritis undergoing anti-TNFα, anti-IL12/23, or anti-IL17 drugs: a 15-year monocentric real-life study.
Lorenzin M; Ortolan A; Cozzi G; Calligaro A; Favaro M; Del Ross T; Doria A; Ramonda R
Clin Rheumatol; 2021 Nov; 40(11):4569-4580. PubMed ID: 34136971
[TBL] [Abstract][Full Text] [Related]
6. Changing rate of serious infections in biologic-exposed rheumatoid arthritis patients. Data from South American registries BIOBADABRASIL and BIOBADASAR.
Ranza R; de la Vega MC; Laurindo IMM; Gómez MG; Titton DC; Kakehasi AM; Brigante A; Benitez A; Ranzolin A; Granel A; Cappuccio AM; Quinteros A; Hayata ALS; Smichowski A; Duarte ÂLBP; Kahlow BS; Andia CS; Brenol CV; Velozo E; Mussano E; Soriano ER; Christopoulos GB; da Rocha Castelar Pinheiro G; de Castro GRW; Casado G; da Silveira Carvalho HM; Exeni IE; da Silveira IG; Petkovic I; Pereira IA; da Costa IP; Rosa JE; Miranda JRS; de Moraes JCB; Bertolo MB; Buhl M; Lázaro MA; da Sauma MFLC; de Medeiros Pinheiro M; Díaz M; de Vechi MVSS; Cerda OL; Astesana P; Curi PF; Louzada-Jr P; Teodoro RB; Toledo RA; Papasidero S; Valim V; Fernandes V; Saurit V; Bianchi WA; ; de Melo Costa Pinto R; Descalzo MA; Gomez-Reino JJ
Clin Rheumatol; 2019 Aug; 38(8):2129-2139. PubMed ID: 31016578
[TBL] [Abstract][Full Text] [Related]
7. Risk factors associated with initiation of a biologic disease modifying anti-rheumatic drug in patients with rheumatoid arthritis: A nested case-control study on 34,925 patients.
Park EH; Shin A; Ha YJ; Lee YJ; Lee EB; Song YW; Kang EH
Joint Bone Spine; 2021 Jan; 88(1):105057. PubMed ID: 32711117
[TBL] [Abstract][Full Text] [Related]
8. Drug survival and reasons for discontinuation of the first biological disease modifying antirheumatic drugs in Thai patients with rheumatoid arthritis: Analysis from the Thai Rheumatic Disease Prior Authorization registry.
Narongroeknawin P; Chevaisrakul P; Kasitanon N; Kitumnuaypong T; Mahakkanukrauh A; Siripaitoon B; Katchamart W;
Int J Rheum Dis; 2018 Jan; 21(1):170-178. PubMed ID: 28737837
[TBL] [Abstract][Full Text] [Related]
9. Clinical predictors of multiple failure to biological therapy in patients with rheumatoid arthritis.
Novella-Navarro M; Plasencia C; Tornero C; Navarro-Compán V; Cabrera-Alarcón JL; Peiteado-López D; Nuño L; Monjo-Henry I; Franco-Gómez K; Villalba A; Balsa A
Arthritis Res Ther; 2020 Dec; 22(1):284. PubMed ID: 33298140
[TBL] [Abstract][Full Text] [Related]
10. Factors associated with the achievement of biological disease-modifying antirheumatic drug-free remission in rheumatoid arthritis: the ANSWER cohort study.
Hashimoto M; Furu M; Yamamoto W; Fujimura T; Hara R; Katayama M; Ohnishi A; Akashi K; Yoshida S; Nagai K; Son Y; Amuro H; Hirano T; Ebina K; Uozumi R; Ito H; Tanaka M; Ohmura K; Fujii T; Mimori T
Arthritis Res Ther; 2018 Aug; 20(1):165. PubMed ID: 30075810
[TBL] [Abstract][Full Text] [Related]
11. Patient characteristics influence the choice of biological drug in RA, and will make non-TNFi biologics appear more harmful than TNFi biologics.
Frisell T; Baecklund E; Bengtsson K; Di Giuseppe D; Forsblad-d'Elia H; Askling J;
Ann Rheum Dis; 2018 May; 77(5):650-657. PubMed ID: 29237621
[TBL] [Abstract][Full Text] [Related]
12. Utilization of biologic disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis and cancer.
Pundole X; Zamora NV; Siddhanamatha H; Lin H; Tayar J; Hong LC; Li L; Suarez-Almazor ME
Clin Rheumatol; 2020 Mar; 39(3):787-794. PubMed ID: 31853733
[TBL] [Abstract][Full Text] [Related]
13. Malignant Neoplasms in Patients With Rheumatoid Arthritis Treated With Tumor Necrosis Factor Inhibitors, Tocilizumab, Abatacept, or Rituximab in Clinical Practice: A Nationwide Cohort Study From Sweden.
Wadström H; Frisell T; Askling J;
JAMA Intern Med; 2017 Nov; 177(11):1605-1612. PubMed ID: 28975211
[TBL] [Abstract][Full Text] [Related]
14. Lymphoma risks in patients with rheumatoid arthritis treated with biological drugs-a Swedish cohort study of risks by time, drug and lymphoma subtype.
Hellgren K; Di Giuseppe D; Smedby KE; Sundström C; Askling J; Baecklund E;
Rheumatology (Oxford); 2021 Feb; 60(2):809-819. PubMed ID: 32810256
[TBL] [Abstract][Full Text] [Related]
15. Assessments of the unmet need in the management of patients with rheumatoid arthritis: analyses from the NOR-DMARD registry.
Olsen IC; Lie E; Vasilescu R; Wallenstein G; Strengholt S; Kvien TK
Rheumatology (Oxford); 2019 Mar; 58(3):481-491. PubMed ID: 30508189
[TBL] [Abstract][Full Text] [Related]
16. Rates, factors, reasons, and economic impact associated with switching in rheumatoid arthritis patients newly initiated on biologic disease modifying anti-rheumatic drugs in an integrated healthcare system.
Rashid N; Lin AT; Aranda G; Lin KJ; Guerrero VN; Nadkarni A; Patel C
J Med Econ; 2016 Jun; 19(6):568-75. PubMed ID: 26766553
[TBL] [Abstract][Full Text] [Related]
17. EQ-5D utility, response and drug survival in rheumatoid arthritis patients on biologic monotherapy: A prospective observational study of patients registered in the south Swedish SSATG registry.
Jørgensen TS; Turesson C; Kapetanovic M; Englund M; Turkiewicz A; Christensen R; Bliddal H; Geborek P; Kristensen LE
PLoS One; 2017; 12(2):e0169946. PubMed ID: 28151971
[TBL] [Abstract][Full Text] [Related]
18. Real-world clinical experience of biological disease modifying anti-rheumatic drugs in Malaysia rheumatoid arthritis patients.
Tan BE; Lim AL; Kan SL; Lim CH; Tsang EEL; Ch'ng SS; Mohd Noor N; Mohd Jamid N; Teh CL; Joshua Thundyil R; Loh YL; Chong HC; Ong SG; Mohamed Ismail A; Lee YYL; Gun SC
Rheumatol Int; 2017 Oct; 37(10):1719-1725. PubMed ID: 28695274
[TBL] [Abstract][Full Text] [Related]
19. Severe adverse drug reactions to biological disease-modifying anti-rheumatic drugs in elderly patients with rheumatoid arthritis in clinical practice.
Leon L; Gomez A; Vadillo C; Pato E; Rodriguez-Rodriguez L; Jover JA; Abasolo L
Clin Exp Rheumatol; 2018; 36(1):29-35. PubMed ID: 28598787
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and drug retention of tofacitinib in rheumatoid arthritis: from the nationwide Korean College of Rheumatology Biologics registry.
Jung JY; Lee E; Kim JW; Suh CH; Kim HA
Clin Exp Rheumatol; 2023 May; 41(5):1034-1041. PubMed ID: 36062753
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
